Short Interest in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Increases By 8.2%

iTeos Therapeutics, Inc. (NASDAQ:ITOS) was the recipient of a significant growth in short interest in June. As of June 15th, there was short interest totalling 2,240,000 shares, a growth of 8.2% from the May 31st total of 2,070,000 shares. Currently, 8.1% of the company’s stock are sold short. Based on an average daily volume of 435,500 shares, the days-to-cover ratio is presently 5.1 days.

iTeos Therapeutics Stock Performance

Shares of ITOS traded down $0.66 during trading hours on Tuesday, hitting $14.35. 129,426 shares of the company were exchanged, compared to its average volume of 358,012. The firm’s 50 day moving average is $15.20 and its 200-day moving average is $12.53. iTeos Therapeutics has a 52 week low of $8.20 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings results on Friday, May 10th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.05). As a group, equities research analysts forecast that iTeos Therapeutics will post -4.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Several large investors have recently made changes to their positions in ITOS. PNC Financial Services Group Inc. raised its holdings in iTeos Therapeutics by 131.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock valued at $25,000 after acquiring an additional 1,299 shares in the last quarter. Federated Hermes Inc. raised its holdings in iTeos Therapeutics by 4,648.4% in the 4th quarter. Federated Hermes Inc. now owns 2,944 shares of the company’s stock valued at $32,000 after acquiring an additional 2,882 shares in the last quarter. Gladius Capital Management LP raised its holdings in iTeos Therapeutics by 48.7% in the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock valued at $34,000 after acquiring an additional 1,026 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in iTeos Therapeutics by 348.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,140 shares of the company’s stock valued at $45,000 after acquiring an additional 3,216 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in iTeos Therapeutics by 268.5% in the 4th quarter. Signaturefd LLC now owns 4,481 shares of the company’s stock valued at $49,000 after acquiring an additional 3,265 shares in the last quarter. Institutional investors and hedge funds own 97.16% of the company’s stock.

Analyst Upgrades and Downgrades

ITOS has been the topic of a number of recent research reports. Wedbush restated an “outperform” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research note on Monday, June 17th. HC Wainwright boosted their target price on iTeos Therapeutics from $44.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, May 13th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.